Final NHS ‘no’ for obesity pill Mysimba
An appeal to get NHS funding for Mysimba as a means for controlling weight has failed, with cost-regulators publishing final guidelines rejecting the drug.
Read More
Tag: naltrexone/bupropion
Draft NICE rejection for Orexigen’s weight-loss pill
The National Institute for Health and Care Excellence has published draft guidelines turning down Orexigen’s weight loss pill Mysimba for routine NHS use.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
